Swiss drugmaker Novartis is to cut 450 jobs in the United States over the next two years as it gradually shuts a generics manufacturing plant in... ...http://feeds.reuters.com/~r/reuters/INhealth/~3/zSk1r-Ces9s/novartis-to-shut-u-s-generics-plant-cut-450-jobs-idINKBN1CO17W
ZURICH (Reuters) - Novartis said on Wednesday a long term study of its Revolade drug showed good results in treating chronic and persistent... ...http://feeds.reuters.com/~r/reuters/INhealth/~3/qsGduNPQM44/novartis-says-revolade-shows-long-term-disease-control-for-chronic-persistent-immune-thrombocytopenia-idINKBN1CN0IM
We would like to inform you that the meeting of the Board of Directors of the Company is scheduled to be held on Friday, November 10, 2017. ...http://www.moneycontrol.com/news/announcements/novartis-india39s-board-meeting-heldnovember-10-2017_9847061.html
By Michael Erman and Divya Grover REUTERS - Mylan NV's long-awaited U.S. approval for its generic version of rival Teva's blockbuster multiple... ...http://www.sify.com/finance/mylan-surges-teva-slumps-after-fda-approves-copaxone-copy-news-health-rkfkckcacddaa.html
Pharma major Novartis India on Monday said that it will buy back shares worth Rs 231.15 crore representing 12.26 per cent of the total paid up... ...http://smetimes.tradeindia.com/smetimes/news/industry/2017/Sep/25/novartis-india-to-buy-back-shares2591715.html
MP-NAT however test execution was...